Rhumbline Advisers Surface Oncology, Inc. Transaction History

Rhumbline Advisers

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.42 - $3.15 $58,770 - $130,372	-41,388 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.65 - $5.08 $10,745 - $20,599	-4,055 Reduced 8.92%	41,388 $122,000
Q4 2021 Feb 10, 2022	SELL	$4.73 - $7.9 $3,996 - $6,675	-845 Reduced 1.83%	45,443 $217,000
Q3 2021 Nov 12, 2021	BUY	$5.16 - $7.98 $9,546 - $14,763	1,850 Added 4.16%	46,288 $350,000
Q2 2021 Aug 05, 2021	BUY	$6.45 - $9.09 $286,625 - $403,941	44,438 New	44,438 $332,000
Q2 2019 Aug 14, 2019	SELL	$2.75 - $4.89 $31,066 - $55,242	-11,297 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$4.11 - $5.88 $46,430 - $66,426	11,297 New	11,297 $54,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.